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Case repOrt
Anti-G is commonly present with anti-D and/or anti-C and 
can confuse serological investigations. In general, anti-G is 
not considered a likely cause of severe hemolytic disease of the 
fetus and newborn (HDFN), but it is important to differentiate 
it from anti-D in women who should be administered anti-D 
immunoglobulin prophylaxis. We report one woman with 
three pregnancies severely affected by anti-C+G requiring 
intrauterine treatment and a review of the literature. In our 
case, the identification of the correct antibody was delayed 
because the differentiation of anti-C+G and anti-D+C was not 
considered important during pregnancy since the father was 
D–. In addition, anti-C+G and anti-G titer levels were not found 
to be as reliable as is generally considered in Rh immunization. 
Severe HDFN occurred at a maternal anti-C+G antibody titer of 
8 and anti-G titer of 1 in comparison with the critical titer level 
of 16 or more in our laboratory. Close collaboration between the 
immunohematology laboratory and the obstetric unit is essential. 
In previously affected families, early assessment for fetal anemia 
is required even when titers are low. Immunohematology 
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Anti-D is the most common antibody responsible for 
severe hemolytic disease of the fetus and newborn (HDFN), 
but antibodies against other antigens belonging to the Rh 
blood group system can also cause HDFN. G, first described 
by Allen and Tippett,1 is part of the Rh blood group system 
and is dependent on expression of both the RHCE*Ce and 
RHD alleles. There are some exceptions, but most individuals 
who do not carry an RHD or RHCE*Ce allele would be 
expected to be negative for G. Anti-G often presents with 
anti-D and/or anti-C, but seldom alone. Anti-G should be 
suspected in cases where the anti-C titer is higher than the 
anti-D titer and confirmed by additional tests.2,3 Anti-G is 
present in approximately 30 percent of cases with apparent 
anti-D+C.4
Anti-G has been associated with HDFN. A few cases have 
been reported where anti-G was the probable cause of severe 
HDFN, but usually the disease is mild and does not require 
therapeutic intervention in the offspring.3,4–9 A case initially 
considered anti-D+C may turn out to be anti-C+G instead, and 
in these cases, anti-D prophylaxis should be administered to 
prevent anti-D alloimmunization and manifestation of HDFN 
in subsequent pregnancies.
In this case report, we describe the outcomes of three 
pregnancies of a Caucasian woman and her African husband, 
where anti-C+G caused severe HDFN requiring intrauterine 
(IU) transfusions.
Case Report
The patient had a history of two miscarriages and one 
extrauterine pregnancy. Subsequently, she had a normal 
pregnancy, where antenatal antibody screening was negative. 
In the following pregnancies, alloimmunization was identified, 
resulting in three cases of severe HDFN. In this case report, 
we present these affected pregnancies, designated as the first, 
second, and third (Table 1). According to the national protocol 
for antenatal antibody screening, maternal sampling began 
at 8–12 weeks of gestation in all pregnancies. The postnatal 
blood samples were drawn on the day of delivery.
In her first affected pregnancy (in 2009), the antibody 
screening was positive for what were at the time assumed 
to be anti-D and anti-C. Followed monthly, the antibody 
titers remained at moderate levels (4–8) until 34 weeks 
of gestation. Because the titer level was below the critical 
level of 16, ultrasound examinations to detect fetal anemia 
were not considered necessary. At 37 weeks of gestation, 
an emergency caesarean section was performed because of 
reduced fetal movements and a sinusoidal heart rate pattern in 
cardiotocography. A D– boy was delivered with a hemoglobin 
(Hb) of 3.1 g/dL and a positive direct antiglobulin test (DAT). 
Unexpectedly, the anti-D+C titer on a sample taken 5 days 
prior to the delivery and available postnatally was 128. 
Immediately postnatally, the anti-D+C titer was 64. The 
anti-C titer was higher than the anti-D titer, as had been the 
case already during the pregnancy, thus prompting suspicion 
of anti-G instead of anti-D. The infant recovered well after 
successful treatment with red blood cell (RBC) transfusion 
and treatment with intravenous immunoglobulin (IVIG).
At the beginning of her second affected pregnancy 
(in 2012), anti-D–like antibody, anti-C, and anti-Jka were 
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identified. The anti-D+C titer was 16 and the anti-Jka titer was 
1. The antibody levels were followed monthly/fortnightly, and 
they remained unchanged during the pregnancy. Because the 
father was D–C+, at 16+2 weeks of gestation the fetus was 
genotyped from amniotic fluid sampling and found positive for 
a RHD-CE-D hybrid gene that is predicted to express no D and 
instead expresses an altered C. The fetus was then carefully 
monitored noninvasively with ultrasound examinations. 
No evidence of fetal anemia was apparent until 23 weeks of 
gestation, when the peak systolic velocity (PSV) in the middle 
cerebral artery (MCA) Doppler examinations exceeded 1.5 
multiples of median (MoM). In cordocentesis at 24+1 weeks, 
the fetal Hb was 7.4 g/dL. A total of five IU transfusions 
were performed successfully between 24+1 and 32+6 weeks 
of gestation. Vaginal delivery was induced at 34 weeks and a 
slightly premature but otherwise healthy girl was born with 
a Hb of 14.1 g/dL and a negative DAT. Neonatal treatment 
included IVIG, phototherapy, and two top-up transfusions. 
Anti-C+G was confirmed postnatally.
At the beginning of her third affected pregnancy, in 
2013, anti-C, anti-G, and anti-Jka were identified. During 
the pregnancy, the titers remained stable: 8–16 for anti-C+G, 
2 for anti-G, and 1 for anti-Jka. The fetus was genotyped 
from amniotic cells as a RHD-CE-D hybrid at 21+1 weeks of 
gestation. Weekly ultrasound examinations were begun at 
22+6 weeks. Middle cerebral artery PSV stayed under 1.29 
MoM until 30+0 weeks, when it reached 1.4 MoM. Given 
the mother’s history, the last finding gave reason to suspect 
anemia, and the first IU transfusion was then scheduled. The 
Hb at the first transfusion was 8.8 g/dL. A total of three IU 
transfusions were performed between 30+5 and 34+6 weeks 
of gestation. Labor was induced at 36+0 weeks, and a healthy 
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Table 1. The courses and outcomes of three pregnancies (in the years 2009, 2012, and 2013) of an alloimmunized D–C–c+E–e+Jk(a–b+) 
mother
2009 2012 2013
Antibody Titer Titer cells Antibody Titer Titer cells Antibody Titer Titer cells
Prenatal work-up Anti-D+C 4–8 R1r Anti-D+C 16 R1r Anti-C+G 8–16 R1r




Follow-up Monthly antibody levels Monthly/fortnightly antibody levels Monthly/fortnightly antibody levels
Weekly/fortnightly MCA PSV flow, MoM Weekly/fortnightly MCA PSV flow, MoM
Intervention Emergency CS at 37 weeks (reduced fetal 
movements, sinusoid cardiotocography)
IU × 5, Hb (between 24 and 34 weeks), 
induction of labor at 34 weeks
IU × 3, Hb (between 31 and 35 weeks), 
induction of labor at 36 weeks
Delivery D– boy, DAT+ D– girl, DAT– D– boy, DAT+
Hb 3.1 g/dL Hb 14.1 g/dL Hb 14 g/dL
Postnatal work-up Anti-D+C* 128 R1r Anti-C+G
‡ 8 R1r Anti-C+G 4 R1r
64–128 r´r Anti-G 1 R2r Anti-G 2 R2r
Anti-D+C† 64 r´r Anti-Jka 1 rr Anti-Jka 1 rr
128 R1r Anti-C+G
§ 2 R1r
Anti-C+G suspected 4 r´r
Anti-Jka detected 1 R2r
Treatment IVIG, red cell transfusion IVIG, phototherapy, red cell transfusion ×2 IVIG ×3, phototherapy
*Sample taken 5 days prior to the delivery; result available 1 day postpartum.
†Sample taken on the day of delivery.
‡Anti-C+G confirmed postnatally.
§Sample taken from umbilical cord.
MCA = middle cerebral artery; PSV = peak systolic velocity, cm/sec; MoM = multiples of median; CS = caesarean section; IU = intrauterine; Hb = hemoglobin; 
DAT = direct antiglobulin test; IVIG = intravenous immunoglobulin.
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boy was born with a Hb of 14 g/dL and a positive DAT. The 
child received IVIG treatment (× 3) and phototherapy, with the 
latter continued at home after discharge from the hospital.
Materials and Methods
All blood samples and amniotic fluid samples were 
analyzed in the Finnish Red Cross Blood Service (in Helsinki), 
which is a national reference laboratory to which the antenatal 
screening for RBC antibodies is centralized. In the second 
affected pregnancy, in 2012, a blood sample was also sent to 
the International Blood Group Reference Laboratory (IBGRL) 
in Bristol, UK, where absorption studies were performed to 
differentiate anti-G from anti-D and anti-C.
ABO and D typing of RBC samples from the mother were 
performed with an analyzer (PK7300, Olympus Corporation, 
Tokyo, Japan) on microtiter plates.
Antibody screening, identification, and DAT studies were 
carried out with a gel-based analyzer (Diamed ID GelStation, 
DiaMed, Cressier, Switzerland). Antibody screening and 
identification were performed using a gel method (LISS/
Coombs cards, Bio-Rad, Cressier, Switzerland) for untreated 
RBCs. Antibody identification with enzyme (papain)-treated 
RBCs in a gel method (NaCl card, DiaMed) was also used. 
A DAT was performed on the infant’s cord blood sample 
using polyspecific antihuman globulin (AHG) (anti-IgG and 
anti-C3D, Bio-Rad) in a gel method (LISS/Coombs cards). 
Serologic phenotyping was carried out with specific reagent 
gel cards (Bio-Rad).
Titrations were performed using the tube method for 
indirect antiglobulin test and R1r reagent RBCs for anti-D, anti-
D+C, and anti-C; r ŕ for anti-C; and R2r for anti-G (because 
reagent cells with only C or G antigen were not available for 
routine use). During the first affected pregnancy, only R1r 
cells were used in titration of anti-D+C, but after delivery of 
the severely anemic D– child, titration was also performed 
with r ŕ cells. In the second affected pregnancy, cells used for 
titrating anti-D+C, anti-C, and anti-G were R1r, r ŕ, and R2r, 
respectively, throughout the pregnancy. In the third affected 
pregnancy, the titer cells used were R1r for anti-C+G and R2r 
for anti-G throughout the pregnancy. Titration for anti-Jka 
was performed with rr Jk(a+b+) reagent RBCs.
Genotyping of the fetal RHD and RHCE genes was carried 
out from amniotic cells using polymerase chain reaction 
with sequence specific primers (PCR-SSP) (PCR-SSP, Inno-
Train, Kronberg, Germany) according to the manufacturer’s 
instructions.
Results
The Caucasian mother was phenotyped as D–C–c+E–e+; 
Jk(a–b+) and the African father as D–C+c+E–e+; Jk(a+b–). 
The father carried the RHD-CE-D hybrid, which encodes 
an altered C that reacts more weakly than a conventional C 
when using serologic methods. The father was the same in all 
pregnancies.
In the first affected pregnancy, the anti-D+C titer remained 
4–8 using D+C+ (R1r) cells followed monthly. The titer was 
128 using D–C+ (r ŕ) cells on a sample taken 5 days prior to 
the delivery and 64 immediately postnatally.
In the second affected pregnancy, the anti-D+C titer was 
16 using D+C+ (R1r) and D–C+ (r ŕ) cells, and 2 with D+C– 
(R2r) cells. A maternal blood sample had also been sent to 
the IBGRL in Bristol, UK, where anti-C+G and anti-Jka were 
confirmed and anti-D ruled out. The postpartum maternal 
anti-C+G titer was 8, and anti-G and anti-Jka titers were both 
1; the anti-C+G titer from cord blood was 4 and anti-G titer 
was 1; anti-Jka was not detected.
During the third affected pregnancy, the antibody titers 
remained stable: 8–16 for anti-C+G using D+C+ (R1r) cells, 
2 for anti-G using D+C– (R2r) cells, and 1 for anti-Jka. The 
postpartum maternal anti-C+G and anti-G titers were 4 and 2, 
respectively; anti-Jka titer was 1 and not obtained for analysis 
from the cord blood sample.
Discussion
In our patient, anti-C was the dominant antibody in all 
affected pregnancies, including the first, as could be confirmed 
retrospectively. The finding of a stronger anti-C compared 
with anti-D led to the suspicion of anti-G. In the first affected 
pregnancy, antibody levels remained low until a rapid increase 
in the final weeks before term, resulting in signs of fetal distress 
and an emergency caesarean section of a severely anemic 
child. The last titer level 3 weeks earlier was 8 but had risen 
to 128 by the time of delivery. In the following pregnancies, 
despite the fact that the antibody titers remained at moderate 
levels (2–16), IU transfusions were required.
Though there are several case reports in the literature of 
HDFN caused by anti-G/anti-C+G, to our knowledge, only 
one of them required IU transfusion: a mother with a history 
of several affected pregnancies presented with severe HDFN 
caused by anti-C+G in a twin pregnancy. Maternal IVIG and 
plasmapheresis were required before IU RBC transfusions 
could be initiated, and despite intensive monitoring, one twin 
126 IMMUNOHEMATOLOGY, Volume 31, Number 3, 2015
was lost and the other needed prolonged treatment including 
phototherapy, RBC transfusions, and erythropoietin injec-
tions.9 In a case report by Hadley et al., anti-G was found to be 
the cause of severe HDFN; cordocentesis was planned but found 
impossible to perform, and after delivery, the infant required 
several exchange transfusions.4 The third reported severe 
case of HDFN with anti-C+G was described by Jakobowicz 
and Simmons.8 Thus, anti-G can be clinically significant in 
pregnancy and may contribute to the development of moderate 
or severe HDFN, although most reported cases have been 
mild. For example, Muller et al. reported a typical case where 
anti-C+G was mistaken for anti-D+C in a primigravida who 
had received RBC transfusions prior to her pregnancy. After 
delivery of a D– baby, anti-C+G was identified in maternal 
blood by adsorption and elution, but no anti-D was detected.3 
Lenkiewicz and Zupanska reported a pregnancy where anti-
C+G antibodies were responsible for moderate hemolytic 
disease of the newborn, and, based on titration results, anti-G 
levels were much higher than anti-C.10
Anti-G is only rarely the single antibody responsible for 
HDFN, but is more often expressed with anti-D, anti-C, or 
both. Palfi and Gunnarsson analyzed the D/C/G antibody 
combinations in 27 pregnancies and found that anti-G was 
present in 24 cases, and in 4 of the 27 cases, anti-C+G was 
identified without anti-D; anti-G was not found alone in any 
of these cases.6 Interestingly, Huber and coworkers reported 
a patient who did have anti-G as the sole cause of moderate 
hemolytic disease of the newborn—anti-D and anti-C were 
excluded.11
In our case, the affected fetuses had inherited the hybrid 
allele RHD-CE-D from their father. The allele codes a D– and 
weak C+ phenotype. G is intact. Thus, both anti-C and anti-G 
could find the target antigens on the RBCs of the fetuses.
Furthermore, our case demonstrates that anti-C or anti-G 
titers are poor predictors of the outcome in an immunized 
pregnancy. In our facility, monitoring of pregnancies at 
high risk for HDFN is planned in collaboration with the 
immunohematology laboratory and the obstetric unit. 
Antibody screening, identification, and follow-up of antibody 
levels are carried out monthly or every 2 weeks. Usually, if 
critical antibody titer levels of 16 are reached, fetal ultrasound 
examinations begin at 18 weeks of gestation and continue 
weekly/fortnightly throughout the pregnancy. Fetal well-being 
evaluated with serial ultrasound for signs of hydrops and 
Doppler measurement of the PSV of the MCA form the basis 
for follow-up in immunized pregnancies. In anemic fetuses, 
lower blood viscosity and increased cardiac output result in 
a higher PSV; a threshold value of 1.5 MoM is predictive of 
moderate to severe anemia, whereas levels lower than 1.29 are 
considered normal.12,13 This noninvasive method has replaced 
the need for assessment of amniotic bilirubin levels. Moreover, 
fetal RHD and RHCE genotyping from maternal serum is now 
feasible, although blood groups other than Rh still need to be 
analyzed from amniocytes.13
Appropriate titer cells are important in the estimation of 
the role of anti-G. A significant number of cases where apparent 
anti-D+C are identified may actually contain only anti-C+G 
and lack anti-D.14 Anti-G should be considered if anti-C titer 
levels exceed or reach the levels of anti-D titers.3 In our case, 
cells used in titration were R1r for anti-D+C, R2r for anti-D 
and anti-G, and r ŕ for anti-C. The titer levels obtained with 
R1r cells were consistently higher than with R2r in all three 
pregnancies, indicating anti-C as the stronger antibody. In 
general, in our laboratory, when anti-D+C are identified, only 
R1r cells are used in titration. Anti-G should be suspected prior 
to titration if the antibody identification panel shows stronger 
reactions for anti-C than anti-D. Then, if titrations performed 
with R1r, R2r, and/or r ŕ cells also indicate the possibility of 
anti-G, additional tests should be carried out. In our laboratory, 
anti-G is demonstrated and anti-D ruled out with absorption 
studies performed concurrently with D–C+ and D+C– 
reagent RBCs. In many laboratories, differential absorption 
and elution is the method of choice, and is recommended for 
the differentiation of anti-G from anti-D.2–4,6,10,11 Furthermore, 
rare rGr cells may also be used in titration.6,7,11 National and 
international blood group reference laboratories may be of use 
in cases where antibody identification by in-house methods is 
challenging.
Identifying anti-G in serum that initially seems to contain 
anti-D+C is important because D– women shown to have anti-
C+G but not anti-D should receive anti-D immunoglobulin 
prophylaxis when carrying or having delivered a D+ child. 
Failure to recognize these cases endangers future pregnancies, 
since alloimmunization may develop. Furthermore, if the 
father is D–, the identification of anti-C+G should be discussed, 
because an incorrect report of anti-D+C may lead to unnecessary 
distress, paternity testing, and social consequences. The 
number of reported anti-G cases is still low. Nevertheless, 
anti-G is more common than has traditionally been thought, 
and may contribute to the development of severe HDFN.
In conclusion, if a pregnant woman seems to have 
anti-D and anti-C, with anti-C being the stronger antibody, 
it is important to test for anti-G. Primarily, if anti-D can be 
excluded, the woman requires anti-D prophylaxis. In addition, 
anti-G can, especially in combination with anti-C, cause severe 
HDFN, even with low titer levels.
R. Jernman et al.
IMMUNOHEMATOLOGY, Volume 31, Number 3, 2015 127
References
 1. Allen FH, Tippett PA. A new Rh blood type which reveals the 
Rh antigen G. Vox Sang 1958;3:321–30.
 2. Shirey RS, Mirabella DC, Lumadue JA, et al. Differentiation 
of anti-D, -C and -G: clinical relevance in alloimmunized 
pregnancies. Transfusion 1997;37:493–6.
 3. Muller CL, Schucker JL, Boctor FN. When anti-G and anti-C 
antibodies masquerade as anti-D antibody. J Matern Fetal 
Neonat Med 2011;24:193–4.
 4. Hadley AG, Poole GD, Poole J, et al. Haemolytic disease of the 
newborn due to anti-G. Vox Sang 1996;71:108–12.
 5. Cash K, Brown T, Strupp A, et al. Anti-G in a pregnant patient. 
Transfusion 1999;39:531–3.
 6. Palfi M, Gunnarsson C. The frequency of anti-C + anti-G in 
the absence of anti-D in alloimmunized pregnancies. Transfus 
Med 2001;11:207–10.
 7. Schultze TJ, Goebel M, Scharberg EA, et al. Development of 
anti-G, anti-C and anti-Jk(b) in a 22-year old mother in her 
fourth pregnancy. Transfus Med Hemother 2013;40:207–9.
 8. Jakobowicz R, Simmons RT. Iso-immunization in a mother 
which demonstrates the “new” Rh blood antigen G (rhG) and 
anti-G (rhG). Med J Aust 1959;46:357–8.
 9. Trevett TN Jr, Moise KJ Jr. Twin pregnancy complicated by 
severe hemolytic disease of the fetus and newborn due to 
anti-G and anti-C. Obstet Gynecol 2005;106:1178–80.
 10. Lenkiewicz B, Zupanska B. Correspondence: clinical 
significance of anti-G. Transfus Med 2002;12:221.
 11. Huber AR, Leonard GT, Driggers RW, et al. Case report: 
moderate hemolytic disease of the newborn due to anti-G. 
Immunohematology 2006;22:166–70.
 12. Eder AF. Update on HDFN: new information on long-standing 
controversies. Immunohematology 2006;22:188–95.
Severe HDFN caused by anti-C+G
 13. Geaghan SM. Diagnostic laboratory technologies for the fetus 
and neonate with isoimmunization. Semin Perinatol 2011; 
35:148–54.
 14. Maley M, Babb R, Chapman CE, et al. Identification and 
quantification of anti-D, -C and -G in alloimmunized pregnant 
women. Transfus Med 2001;11:443–6.
Riina Jernman, MD, PhD (corresponding author), Specialist 
in Obstetrics and Gynecology, Department of Obstetrics and 
Gynecology, University of Helsinki and Helsinki University Hospital, 
P.O. Box 140, 00029 HUS, Helsinki, Finland, riina.jernman@
hus.fi; Vedran Stefanovic, MD, PhD, Specialist in Obstetrics and 
Gynecology, Department of Obstetrics and Gynecology, University 
of Helsinki and Helsinki University Hospital, Helsinki, Finland; 
Anu Korhonen, MSc, Laboratory Specialist; Katri Haimila, PhD, 
Laboratory Specialist; Inna Sareneva, MSc, Laboratory Specialist; 
Kati Sulin, MSc, Laboratory Specialist; Malla Kuosmanen, PhL, 
Biologist; Susanna Sainio, MD, PhD, Specialist in Obstetrics and 
Gynecology, Finnish Red Cross Blood Service, Helsinki, Finland.
